Clinical Dilemmas in Viral Liver Disease
ISBN: 9781405179058 | 1405179058
Edition: 1stFormat: Paperback
Publisher: Wiley-Blackwell
Pub. Date: 4/26/2010
Why Rent from Knetbooks?
Because Knetbooks knows college students. Our rental program is designed to save you time and money. Whether you need a textbook for a semester, quarter or even a summer session, we have an option for you. Simply select a rental period, enter your information and your book will be on its way!
Top 5 reasons to order all your textbooks from Knetbooks:
- We have the lowest prices on thousands of popular textbooks
- Free shipping both ways on ALL orders
- Most orders ship within 48 hours
- Need your book longer than expected? Extending your rental is simple
- Our customer support team is always here to help
Viral hepatitis is an extremely complex disease to treat, and the patient care team faces clinical challenges on a daily basis. In the past, answers to specific questions could be located only after extensive searching or the compilation of information from numerous sources. Now, this one concise reference provides evidence-based guidance on topical clinical questions encountered during diagnosis, treatment, and management of patients with viral liver disease.
Clinical Dilemmas in Viral Liver Disease is a pr... MORE
Clinical Dilemmas in Viral Liver Disease is a pr... MORE
| Investigating the liver | |
| Non-invasive markers of fibrosis - useful or useless? | |
| Liver biopsy in HCV with easy to treat disease - should we bother? | |
| The inactive carrier - what tests should we do for HBeAg negative patients with minimal HBV DNA and near normal LFTs? | |
| Screening for HCC in patients with viral cirrhosis - is ultrasound enough? | |
| HBV pre-treatment sequencing. Prudent precaution or unnecessary lux... MORE | |
| Genomic investigations in viral hepatitis - likely to help or hinder? | |
| Today's therapies | |
| HCV | |
| How should HCV Genotype 1 Non-responders be managed? | |
| How should HCV Genotype 1 patients who relapse or breakthrough be managed? | |
| How should HCV Genotype 2/3 Non-responders be managed? | |
| How should HCV Genotype 2/3 patients who relapse or breakthrough be managed? | |
| How should we treat acute HCV infection? | |
| How should we treat HCV in patients with red cell dyscrasias? | |
| How should we treat HCV in dialysis patients? | |
| How should we treat HCV in patients with a renal transplant? | |
| How should we treat HCV in psychotic patients? | |
| What management strategies can we use for morbid obesity and HCV? | |
| What management strategies are appropriate for Cytopenias and hepatitis C? | |
| How should patients with multiple HCV genotypes be managed? | |
| How should we treat HCV in injecting drug users? | |
| How should we treat HIC and HCV/HBV? | |
| How should we treat HCV, anti LKM antibodies and autoimmune disorders? | |
| How should we manage an easy to treat virus in difficult patients? -HCV in obese cirrhotics with genotype 3 | |
| How should we treat HCV in children? | |
| Controlling symptoms in chronic HCV On and Off Treatment - does anything work? | |
| Complementary therapies in chronic HCV - exploitation or something to offer? | |
| HCV in the post liver transplant patient: what options do we have? | |
| How should we manage viral hepatitis in bone marrow transplant patients? | |
| HBV | |
| What's the best way to manage acute HBV? | |
| How should we manage HBeAg positive patients with near normal LFTs? | |
| How should we manage HBeAg negative patients with minimal changes on liver biopsy? | |
| HBV combination therapy ab initio or add in regimes? | |
| How should we manage HBV infection in children? | |
| HBV and the second pregnancy - what should we do when the first child has failed to respond to vaccination? | |
| How should HBV in surgeons be managed? | |
| What can we do about HBV and the poorly compliant patient? | |
| How can we manage acute liver failure and HBV? | |
| High risk needlestick injuries in vaccine failures? | |
| How best to manage HBV in the immunocompromised patient? | |
| What can we do in Lamivudine and Adefovir resistance? | |
| How do we manage HBV following unsuccessful interferon therapy? | |
| How do we manage co-infection with HBV and HCV? | |
| HDV | |
| HDV | |
| Clinical set up | |
| What is the role of the nurse specialist? | |
| Non specialist management of viral liver disease - cost effective or foolish cost cutting? | |
| The future | |
| Clinical trial design in chronic HCV - with or without PegIFN and ribavirin? | |
| Protease and polymerase inhibitors for HCV | |
| HCV vaccines - coming soon? | |
| HBV - new nucleotides and nucleosides - can we expect any more? | |
| HBV novel drugs: what's in the pipeline? | |
| HBV - therapeutic vaccines - hope or hype? | |
| Novel interferons - is there life in the old dog yet? | |
| On-going controversies | |
| HBV therapy | |
| Is Interferon a valuable first line therapy for HBeAg positive HBV? | |
| Should nucleosides always be used first in HBeAg positive HBV? | |
| HCV | |
| Will most patients with HCV die from their disease? | |
| Table of Contents provided by Publisher. All Rights Reserved. |
Graham R Foster PhD FRCP
Professor of Hepatology, Queen Marys University of London, Blizard Institute of Cell & Molecular Science, The Royal London Hospital, London, UK
K. Rajender Reddy MD, FACP, FACG, FRCP
Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology, Medical Director of Liver Transplantation, University of Pennsylvania, PA, USA
Please wait while this item is added to your cart...
